JPMorgan analyst Chris Schott upgraded Biogen (NASDAQ: BIIB) from Neutral to Overweight with a price target of $300.00 (from $210.00).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades